Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia
The Lancet Regional Health - Western Pacific · 2024-10 · 51 · 101185
DOI: 10.1016/j.lanwpc.2024.101185 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2024-10. Verfasst von Shane Tillakeratne und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, UNSW Sydney, Australia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Department of Health.
Abstract (Originalsprache)
Background
Monitoring hepatitis B virus (HBV) and hepatitis C virus (HCV) liver-related morbidity and mortality is key to evaluate progress towards elimination targets.
Methods
HBV and HCV notifications in NSW, Australia (1995-2022) were linked to hospital and mortality records. Temporal trends in decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and mortality were evaluated among people notified for HBV and HCV. Segmented Poisson regression models were used to assess the impact of the viral hepatitis elimination era (1 January 2015-31 December 2022) on advanced liver disease and mortality.
Findings
During 1995-2022, there were 64,865 people with an HBV notification and 112,277 people with an HCV notification in NSW. Between 2002 and 2022, there were significant reductions in age-adjusted HBV- and HCV-related DC, HCC, and liver-related mortality. Among those with HBV, age-standardised incidence per 1000 person-years (py) in 2002, 2015, and 2022 was 3.08, 1.47, and 1.16 for DC (p < 0.001); 2.97, 1.45, and 0.75 for HCC (p < 0.001); and 2.84, 1.93, and 1.40 for liver-related mortality (p < 0.001). Among those with HCV, age-standardised incidence per 1000 py in 2002, 2015, and 2022, was 5.53, 4.57, and 2.31 for DC (p < 0.001); 2.22, 2.59, and 1.87 for HCC (p < 0.001); and 3.89, 4.73, and 3.16 for liver-related mortality (p < 0.001). In 2022, absolute liver-related mortality per 100,000 population was 0.95 for HBV and 3.56 for HCV. In adjusted analyses, older age, comorbidity, and a history of alcohol use disorder were associated with increased liver-related mortality among those with HBV and HCV.
Interpretation
This population-level study demonstrated declining risks of DC, HCC, and mortality, with HBV-related declines commencing well before elimination era while HCV-related declines were mostly during elimination era. Population liver mortality indicates elimination target achieved for combined viral hepatitis and HBV, but not HCV. Funding: The Kirby Institute, UNSW Sydney, and New South Wales Ministry of Health, Australia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Kirby Institute, UNSW Sydney, Australia.
- School of Population Health, UNSW Sydney, Australia.
- Department of Health Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.
Förderung
- Australian Government Department of Health
Zitieren
APA
Tillakeratne, S., Pearson, S. A., Alavi, M., Hajarizadeh, B., Martinello, M., Law, M., George, J., Amin, J., Matthews, G., Grebely, J., Dore, G. J., & Valerio, H. (2024). Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia. The Lancet Regional Health - Western Pacific, 51, 101185. https://doi.org/10.1016/j.lanwpc.2024.101185
Vancouver
Tillakeratne S, Pearson SA, Alavi M, Hajarizadeh B, Martinello M, Law M, et al. Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia. The Lancet Regional Health - Western Pacific. 2024;51:101185. doi:10.1016/j.lanwpc.2024.101185
BibTeX
@article{Tillakeratne2024,
author = {Tillakeratne, Shane and Pearson, Sallie-Anne and Alavi, Maryam and Hajarizadeh, Behzad and Martinello, Marianne and Law, Matthew and George, Jacob and Amin, Janaki and Matthews, Gail and Grebely, Jason and Dore, Gregory J and Valerio, Heather},
title = {Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia},
journal = {The Lancet Regional Health - Western Pacific},
year = {2024},
volume = {51},
pages = {101185},
doi = {10.1016/j.lanwpc.2024.101185}
}
EUVIMED